![Kenzo Kosuda](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kenzo Kosuda
Director of Finance/CFO at REGiMMUNE Corp.
Kenzo Kosuda active positions
Companies | Position | Start | End |
---|---|---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Director/Board Member | 01/01/2013 | - |
Director of Finance/CFO | 01/01/2013 | - |
Career history of Kenzo Kosuda
Training of Kenzo Kosuda
Keio University | Undergraduate Degree |
Statistics
International
Japan | 3 |
Operational
Director/Board Member | 1 |
Director of Finance/CFO | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
- Stock Market
- Insiders
- Kenzo Kosuda
- Experience